Clinical Trials Logo

Neurocysticercosis clinical trials

View clinical trials related to Neurocysticercosis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03950037 Withdrawn - Clinical trials for Subarachnoid Neurocysticercosis

SANCC: Clinical Trial Early Intervention

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

Subarachnoid neurocysticercosis (SANCC) is a severe infection of the brain by the tapeworm Taenia solium. People who have this infection are usually diagnosed late in the disease process leading to very poor prognosis. This trial studies the safety of early medical intervention in people who have SANCC but do not have symptoms. The trial will enroll 18 participants in Peru.

NCT ID: NCT01584362 Withdrawn - Clinical trials for Tenia Solium Infection

Single Ascending Dose Safety Study of Oxfendazole

OXFEND-02
Start date: August 2016
Phase: Phase 1
Study type: Interventional

This research is being done to learn about the safety in humans of a medicine that is already used in cows and pigs to treat worms. The medicine may be useful for people who have these or other worms. The medicine will be studied first in healthy people, who will be given a very small amount of the medicine once. If the smallest amount of medicine is found to be safe, a slightly higher amount will be given to a new group of volunteers. The highest amount that will be tested is similar to the amount given to animals. If the medicine can be given safely to healthy people in the planned amounts, a later study will be done in people who have worms to see if the medicine kills the worms.

NCT ID: NCT00133458 Withdrawn - Clinical trials for Subarachnoid Cysticercosis

RCT ALB for SA Cysticercosis

Start date: n/a
Phase: Phase 3
Study type: Interventional

This study will enroll 120 individuals diagnosed with subarachnoid cysticercosis, a disease caused by the invasion of the basal part of your brain by a parasite named Taenia solium. Subarachnoid cysticercosis is usually treated with albendazole for one month to kill the parasite. This study will determine if two months of albendazole (ABZ) therapy is better than one-month. The study will last 3 years.